Tuberculosis and human immunodeficiency virus co-infections and their predictors at a hospital-based HIV/AIDS clinic in Uganda

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 12, 2010, Pages 1621-1628

  Nakanjako, Damalie ^a   Mayanja Kizza, H ^a   Ouma, J ^b   Wanyenze, R ^b   Mwesigire, D ^b   Namale, A ^a   Ssempiira, J ^a   Senkusu, J ^a   Colebunders, R ^c,d   Kamya, M R ^a  

^a MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^b Mulago Mbarara Teaching Hospitals' Joint AIDS Program (MJAP)   (Uganda)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Africa; ART; HIV AIDS; TB HIV co infections; Tuberculosis

Indexed keywords

EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE;

ADULT; ARTICLE; BODY MASS; EVALUATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUBERCULOSIS; UGANDA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HOSPITALS, URBAN; HUMANS; MALE; MASS SCREENING; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TUBERCULOSIS; UGANDA;

EID: 78649375532     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Lawn S D, Myer L, Harling G, Orrell C, Bekker L G, Wood R. Determinants of mortality and non-death losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43: 770-776.
2. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21: 713-719.
3. Mukadi Y D, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001; 15: 143-152.
4. Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow- up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 2009; 9: 290.
5. Katwere M, Kambugu A, Piloya T, et al. Clinical presentation and aetiologies of acute or complicated headache among HIV-seropositive patients in a Ugandan clinic. J Int AIDS Soc 2009; 12: 21.
6. HIV Medicine Association, Infectious Diseases Society of America, The Forum for Collaborative HIV Research. HIV/TB co-infection: basic facts. Arlington, VA, USA: IDSA, 2007. http://www.idsociety.org/uploadedFiles/IDSA/ Resources/Fact-Sheets/HIV-TB-Coinfection-Oct-2007.pdf Accessed September 2010.
7. Lawn S D, Myer L, Orrell C, Bekker L G, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19: 2141-2148.
8. Wood R. The case for integrating tuberculosis and HIV treatment services in South Africa. J Infect Dis 2007; 196 (Suppl 3): S497-S499.
9. Venkatesh P A, Bosch R J, McIntosh K, Mugusi F, Msamanga G, Fawzi W W. Predictors of incident tuberculosis among HIV-1- infected women in Tanzania. Int J Tuberc Lung Dis 2005; 9: 1105-1111.
10. Corbett E L, Marston B, Churchyard G J, De Cock K M. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367: 926-937.
11. Ansari N A, Kombe A H, Kenyon T A, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002; 6: 55-63.
12. World Health Organization. Evidence-based tuberculosis diagnosis: a comprehensive resource for evidence syntheses, policies, guidelines and research agendas on TB diagnostics. Geneva, Switzerland: WHO, 2007. http://www.who.int/ tb/dots/ laboratory/policy/en/index1.html Accessed September 2010.
13. Lawn S D, Myer L, Bekker L G, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-1612.
14. Kiwuwa M S, Charles K, Harriet M K. Patient and health service delay in pulmonary tuberculosis patients attending a referral hospital: a cross-sectional study. BMC Public Health 2005; 5: 122.
15. Westreich D, MacPhail P, Van Rie A, et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS 2009; 23: 707-715.
16. Wanyenze R, Kamya M, Liechty C A, et al. HIV counseling and testing practices at an urban hospital in Kampala, Uganda. AIDS Behav 2006; 10: 361-367.
17. Austin J F, Dick J M, Zwarenstein M. Gender disparity amongst TB suspects and new TB patients according to data recorded at the South African Institute of Medical Research laboratory for the Western Cape Region of South Africa. Int J Tuberc Lung Dis 2004; 8: 435-439.
18. Brinkhof M W, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45: 1518-1521.
19. Tindo H, Cesar Cavalcante S, Werneck-Barroso E. Gender differences in tuberculosis in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2004; 8: 388-390.
20. Theuring S, Mbezi P, Luvanda H, Jordan-Harder B, Kunz A, Harms G. Male involvement in PMTCT services in Mbeya Region, Tanzania. AIDS Behav 2009; 13 (Suppl 1): 92-102.
21. Baalwa J, Mayanja-Kizza H, Kamya R M, John L, Kambugu A, Colebunders R. Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active antir etroviral therapy in Uganda. Afr Health Sci 2008; 8: 190-195.
22. Rosen S, Fox M P, Gill C J. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4: e298.
23. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
24. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource limited settings: towards universal access: recommendations for a public health approach (2006 revision). Geneva, Switzerland: WHO, 2006.
25. Teck R, Ascurra O, Gomani P, et al. WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for antiretroviral treatment: relationship to CD4 lymphocyte counts. Int J Tuberc Lung Dis 2005; 9: 258-262.
26. Nakanjako D, Kiragga A, Castelnuovo B, Kambugu A, Munabe Y. Initiating antiretroviral therapy at CD4 counts below 350 cells/Ul. What does this mean to HIV/AIDS care programs in Uganda? In: 48th Annual ICAAC/IDSA 46th Annual Meeting; October 25-28, 2008. Washington DC, USA: Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America, 2008.
27. Bonnet M M, Pinoges L L, Varaine F F, et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 2006; 20: 1275-1279.
28. Lawn S D, Myer L, Bekker L G, Wood R. Tuberculosisassociated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-341.
29. Easterbrook P J. HIV immune reconstitution syndrome in sub-Saharan Africa. AIDS 2008; 22: 643-645.
30. Meintjes G, Lawn S D, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-523.
31. Kambugu A, Meya D B, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46: 1694-1701.
32. Lawn S D, Harries A D, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22: 1897-1908.
33. Lawn S D, Little F, Bekker L G, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23: 335-342.
34. Matee M, Mtei L, Lounasvaara T, et al. Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. BMC Public Health 2008; 8: 68.
35. Steingart K R, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6: 664-674.